A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 1
- Sponsors LEO Pharma
- 16 Jul 2018 Planned End Date changed from 8 Jun 2020 to 1 Nov 2019.
- 16 Jul 2018 Planned primary completion date changed from 24 Feb 2020 to 1 Sep 2018.
- 17 Apr 2018 Status changed from recruiting to active, no longer recruiting.